Osteoporosis and Implant Failure: An Exploratory Case‐Control Study

Becker, William; Hujoel, Philippe P.; Becker, Burton E.; Willingham, Harold

doi:10.1902/jop.2000.71.4.625

Cited by 134 publications

(86 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the prevalence of osteoporosis increases with age and after menopause, the literature reviewed does not show the relationship of the implant failure rate with age and sex. The tactile valuation of bone quality during the preparation of the implant area, and the already achieved primary stability, bring more information that densitometric measurements of peripheral bones about the probability of failure (9).…”

Section: Implants In Subjects With Osteoporosismentioning

confidence: 99%

Implant treatment in patients with osteoporosis

Mellado-Valero

Ferrer-García²,

Calvo-Catalá³

et al. 2009

Med Oral

View full text Add to dashboard Cite

Osteoporosis is very common, particularly in post-menopausal women and is characterized by a decrease in bone mass and strength. Osteoporosis also affects the jawbone and it is considered a potential contraindication to placement of dental implants. The present paper reviews the literature regarding the effect of osteoporosis on osseointegration of implants. Experimental models have shown that osteoporosis affects the process of osseointegration, which can be reversed by treatment. However, studies in subjects with osteoporosis have shown no differences in survival of the implants compared to healthy individuals. Therefore, osteoporosis cannot be considered a contraindication for implant placement. Oral bisphosphonates are the most commonly used pharmacological agents in the treatment of osteoporosis. Although there have been cases of osteonecrosis of the jaw in patients treated with bisphosphonates, they are very rare and it is more usually associated with intravenous bisphosphonates in patients with neoplasms or other serious diseases. Nevertheless, patients treated with bisphosphonates must be informed in writing about the possibility of this complication and must give informed consent. Ceasing to use bisphosphonates before implant placement does not seem to be necessary.

show abstract

Section: Implants In Subjects With Osteoporosismentioning

confidence: 99%

Implant treatment in patients with osteoporosis

Mellado-Valero

Ferrer-García²,

Calvo-Catalá³

et al. 2009

Med Oral

View full text Add to dashboard Cite

show abstract

“…Since osteoporotic patients require particular attention during implant placement, IT has been established as a simple and noninvasive method to assess local bone quality and primary implant stability. [10][11][12][13] It is the purpose of this study to test whether IT is significantly correlated with bone density or not, as assessed by the CBCT in a group of osteopenic and osteoporotic patients.…”

Section: Introductionmentioning

confidence: 99%

Implant Insertion Torque Load Analysis for Mandible using CBCT Images

Venkatakrishnan¹

2017

World Journal of Dentistry

View full text Add to dashboard Cite

show abstract

“…It has been reported that primary stability is decreased at sites of low bone density, for example those in patients with osteoporosis, and this may be a risk factor for implant failure (3). Thus, bone density at the implant placement site appears to be a crucial factor that is correlated with failure rate and primary stability (4,5). In fact, osteoporosis patients who undergo implant treatment have a less favorable outcome than patients with healthy bone (6).…”

Section: Introductionmentioning

confidence: 99%

Intermittent administration of parathyroid hormone enhances primary stability of dental implants in a bone-reduced rabbit model

et al. 2016

View full text Add to dashboard Cite

The aim of the study was to investigate the effect of parathyroid hormone (PTH) on primary stability of dental implants in a bone-reduced model. Ten female New Zealand white rabbits underwent ovariectomy and were administered glucocorticoid to induce osteoporosis. One group was administered PTH intermittently by subcutaneous injection for 4 weeks (PTH-group) and the other group was given injections of saline for 4 weeks (Osteoporosis; OP-group). After the administration period, implants were inserted into the distal femoral epiphyses of each animal. At implant placement, insertion torque (IT) and implant stability quotient (ISQ) were measured. Histological examination revealed newly formed trabecular bone around the implant socket in the PTH-group but not in the OP-group. The trabecular bone structures in the PTH-group appeared thicker than those in the OP-group. In the PTH-group, the mean IT value was significantly greater than that in the OP-group (29.8 ± 6.2 Ncm and 10.0 ± 2.1 Ncm, respectively; P < 0.05). The ISQ value in the PTH-group was significantly higher than that in the OP-group (74.7 ± 11.2 and 55.9 ± 13.5, respectively; P < 0.05). Intermittent PTH administration could be an effective treatment for achieving favorable primary stability of dental implants in patients with osteoporosis. (J Oral Sci 58, 241-246, 2016)

show abstract

Osteoporosis and Implant Failure: An Exploratory Case‐Control Study

Cited by 134 publications

References 21 publications

Implant treatment in patients with osteoporosis

Implant treatment in patients with osteoporosis

Implant Insertion Torque Load Analysis for Mandible using CBCT Images

Intermittent administration of parathyroid hormone enhances primary stability of dental implants in a bone-reduced rabbit model

Contact Info

Product

Resources

About